Show simple item record

dc.contributor.authorGollins, Simon
dc.contributor.authorWest, Nick
dc.contributor.authorSebag-Montefiore, David
dc.contributor.authorMyint, Arthur Sun
dc.contributor.authorSaunders, Mark
dc.contributor.authorSusnerwala, Shabbir
dc.contributor.authorQuirke, Phil
dc.contributor.authorEssapen, Sharadah
dc.contributor.authorSamuel, Leslie
dc.contributor.authorSizer, Bruce
dc.contributor.authorWorlding, Jane
dc.contributor.authorSouthward, Katie
dc.contributor.authorHemmings, Gemma
dc.contributor.authorTinkler-Hundal, Emma
dc.contributor.authorTaylor, Morag
dc.contributor.authorBottomley, Daniel
dc.contributor.authorChambers, Philip
dc.contributor.authorLawrie, Emma
dc.contributor.authorLopes, Andre
dc.contributor.authorBeare, Sandy
dc.date.accessioned2018-04-02T08:44:06Z
dc.date.available2018-04-02T08:44:06Z
dc.date.issued2017-10-24
dc.identifier.citationGollins , S , West , N , Sebag-Montefiore , D , Myint , A S , Saunders , M , Susnerwala , S , Quirke , P , Essapen , S , Samuel , L , Sizer , B , Worlding , J , Southward , K , Hemmings , G , Tinkler-Hundal , E , Taylor , M , Bottomley , D , Chambers , P , Lawrie , E , Lopes , A & Beare , S 2017 , ' Preoperative chemoradiation with capecitabine, irinotecan and cetuximab in rectal cancer : significance of pre-treatment and post-resection RAS mutations ' , British Journal of Cancer , vol. 117 , pp. 1286-1294 . https://doi.org/10.1038/bjc.2017.294en
dc.identifier.issn0007-0920
dc.identifier.otherPURE: 117910179
dc.identifier.otherPURE UUID: e173c88d-c840-4387-87cf-cb6c0481390f
dc.identifier.otherScopus: 85033408230
dc.identifier.otherORCID: /0000-0002-8402-8670/work/50559792
dc.identifier.urihttp://hdl.handle.net/2164/10275
dc.descriptionThis work was funded by Cancer Research UK Bobby Moore Fund (ref C23134A9353). Merck Serono supplied free cetuximab and an educational grant and Pfizer gave free irinotecan and an educational grant. Neither Merck Serono or Pfizer was involved in study design, data analysis or manuscript preparation or had access to study data. Central trial coordination was by Cancer Research UK and University College London Cancer Trials Centre, including data collection and statistical analyses. The Pathology and Tumour Biology laboratory is supported by grants from Yorkshire Cancer Research, the Pathological Society of Great Britain and Ireland, the Academy of Medical Sciences, The Medical Research Council and a National Institute of Health Research Senior Investigator Award. SG was a National Institute for Social Care and Health Research Academic Health Science Collaboration Clinical Research Fellow.en
dc.format.extent9
dc.language.isoeng
dc.relation.ispartofBritish Journal of Canceren
dc.rights© The Author(s) named above. This work is licensed under the Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/en
dc.subjectlocally advanced rectal canceren
dc.subjectcetuximab-containing chemoradiationen
dc.subjectRAS mutationsen
dc.subjectintra-tumoural clonal heterogeneityen
dc.subjecttreatment responseen
dc.subjectnext generation sequencingen
dc.subjectRC0254 Neoplasms. Tumors. Oncology (including Cancer)en
dc.subjectCancer Research UKen
dc.subjectC23134A9353en
dc.subject.lccRC0254en
dc.titlePreoperative chemoradiation with capecitabine, irinotecan and cetuximab in rectal cancer : significance of pre-treatment and post-resection RAS mutationsen
dc.typeJournal articleen
dc.contributor.institutionUniversity of Aberdeen.Health Services Research Uniten
dc.description.statusPeer revieweden
dc.description.versionPublisher PDFen
dc.identifier.doihttps://doi.org/10.1038/bjc.2017.294


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record